Zamtocabtagene autoleucel治疗复发/难治B细胞非霍奇金淋巴瘤:CD20/19串联CAR-T一期试验5年随访
该首次人体一期试验评估非冷冻保存的CD20-CD19串联CAR-T产品zamto-cel治疗复发/难治B细胞非霍奇金淋巴瘤,设两个预设剂量水平,主要终点为最大耐受剂量。共治疗12例患者,未观察到剂量限制性毒性及≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征,最大耐受剂量未达到。 investigator评估的最佳总缓解率为75%,5/12例(42%)达完全缓解且至输注后5年临床评估无复发。
要点
- zamto-cel两个剂量水平均未达到最大耐受剂量,未观察到剂量限制性毒性。
- 未发生≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
- 最佳总缓解率75%,42%患者达完全缓解且5年随访无复发。
核心结论
- zamto-cel在复发/难治B细胞非霍奇金淋巴瘤中未达到最大耐受剂量,风险获益比良好。
- 完全缓解与zamto-cel较高平均最大观察浓度及第6个月后仍可检测到相关。
- 基于 promising 风险获益比,zamto-cel DL2正在关键二期试验中评估。
研究设计与样本
- 首次人体一期临床试验,评估非冷冻保存的CD20-CD19串联CAR-T产品zamto-cel。
- 设两个预设剂量水平:DL1为1×10^6、DL2为2.5×10^6 CAR+ T细胞/kg体重。
- 共治疗12例复发/难治B细胞非霍奇金淋巴瘤患者,每个剂量水平6例。
- 主要终点为最大耐受剂量,次要终点包括不良事件、最佳总缓解和生物标志物评估。
主要发现
- 未观察到剂量限制性毒性,最大耐受剂量未达到。
- 未观察到≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
- 研究者评估的最佳总缓解率为75%。
- 5/12例患者(42%)达到完全缓解,至第12个月无复发,输注后5年临床评估无复发。
- 完全缓解患者中观察到zamto-cel平均最大观察浓度更高、第6个月后仍可检测到zamto-cel,且CD27和CD127表达增加、CAR+中央记忆T细胞扩增增加。
临床怎么用
- zamto-cel在复发/难治B细胞非霍奇金淋巴瘤中显示出可控安全性和持久缓解潜力。
- DL2正在关键二期临床试验中用于复发/难治侵袭性B细胞非霍奇金淋巴瘤患者评估。
局限性
- 样本量小,共12例患者,每个剂量水平仅6例。
- 为一期试验,主要终点为最大耐受剂量,疗效需二期试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 × 106 and DL2, 2.5 × 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.
引用
- Balke-Want H, Gödel P, Schmid C, et al. Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial. Blood Adv. 2026. PMID: 41512222. doi:10.1182/bloodadvances.2025018073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。